Ingevity Corporation (NGVT) shares have gained 33.9% over the past year driven by portfolio transformation, strategic divestitures, and disciplined capital allocation. The company is focusing on high-return markets and targeting $300 million in share repurchases through 2027. However, challenges include weakness in the APT business segment, macroeconomic uncertainties, and softer North American auto production forecasts. NGVT carries a Zacks Rank #3 (Hold) rating.

Ingevity Corporation (NGVT) shares have gained 30.6% over the past year, outperforming its industry. The company's portfolio optimization through divestitures and acquisitions, combined with improved cash flow generation and debt reduction to 2.5X leverage, has boosted investor confidence. NGVT is pursuing growth opportunities in PFAS filtration, biofuels applications, and capacity expansions while planning a $300 million share repurchase program through 2027.

The global activated carbon market is projected to grow from USD 6.1 billion in 2026 to USD 11.1 billion by 2033, with a CAGR of 8.90%. Growth is driven by stricter environmental regulations, increased water treatment infrastructure investment, and rising demand for air purification and industrial applications, particularly in Asia-Pacific.

Ingevity Corporation (NGVT) shares have gained 19.2% year-to-date, outperforming its industry, driven by successful portfolio optimization, divestitures, and increased demand for hybrid vehicle applications. The company reported 14% YoY adjusted EBITDA growth to $115 million in Q2 with expanded margins of 36.6%, and raised its 2026 adjusted EBITDA guidance to $380-$400 million.

Ingevity reported Q2 2025 earnings with mixed results: non-GAAP EPS exceeded expectations at $1.39, but revenue declined 6.5% to $365.1 million. The company saw improved profitability and cash flow, with a significant goodwill impairment in Advanced Polymer Technologies.

Ingevity Corporation reported a Q2 2024 loss of $283.7 million or $7.81 per share, down from a profit of $35.5 million a year ago. Revenues declined 18.9% year-over-year to $390.6 million, missing estimates. The company revised its sales and adjusted EBITDA guidance for 2024.

The article analyzes the recent ratings and price targets of 5 financial analysts for Ingevity, a chemical manufacturer. The analysts have a mixed outlook, with an average 12-month price target of $55.2 and a range of ratings from 'Outperform' to 'Underperform'. The company's financial performance, including declining revenue, low profitability, and high debt levels, are also discussed.

Ingevity Corporation has expanded its Capa caprolactone distribution network by selecting Ultrapolymers Group as the distributor for Capa Bioplastics in Europe. This move aligns with Ingevity's growth strategy in the region.

Ingevity Corp has finalized the termination of a significant crude tall oil supply agreement with GP Pine Chemicals, a subsidiary of Georgia-Pacific. The termination provides Ingevity more flexibility as it plans to restructure its Performance Chemicals business segment to focus on specialty chemicals markets.

Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Hawkins (HWKN) sees strong growth in the Water Treatment segment in the fiscal fourth quarter.

American Vanguard's (AVD) U.S. crop business registers strong sales of granular soil insecticides, herbicides and cotton and peanut products in Q1.